Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

This is the first randomized trial directly comparing pulse-modulated Holmium:YAG laser and thulium fiber laser treatment of kidney stones during ureteroscopy.

Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the ...

The woman was in severe pain and discomfort, unable to focus on her job, eat, or sleep properly. She was exhausted, but had ...

Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

Kaplan-Meier analysis showed a statistically significant difference in overall survival favoring immediate treatment (log-rank p = 0.002), though recurrence-free survival did not differ significantly ...

Emma Dimery joined the clinical trial after running out of treatment options. For two years, she's been cancer free.

Valentina Milanova believed she 'was dying' when she experienced her first period aged nine, but has since set up a business ...

Ms Milanova, now 30, got her first period at just nine but, without any education about menstruation, feared she was gravely ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...